List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
Alivio Therapeutics Inc
Allander Biotechnologies LLC
BIOCND Inc
Clevexel Pharma SAS
GlycoMira Therapeutics Inc
Humanetics Corp
Lakewood-Amedex Inc
Matrix Biomed Inc
Moberg Pharma AB
Spectrum Pharmaceuticals Inc
Oral Mucositis - Drug Profiles
BCD-600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoleucovorin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suramin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tempol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Dec 03, 2018: Spectrum Pharmaceuticals announces positive results from phase 2 trial evaluating use of oral Leucovorin to potentially Mitigate Mucositis in patients treated with FOLOTYN (pralatrexate)
May 02, 2018: Moberg Pharma: U.S. Patent Granted For BUPI
Sep 01, 2017: Canadian patent Granted for BUPI
Sep 01, 2017: Phase 2-results for BUPI Published
Oct 19, 2016: European Patent granted for BUPI
Jan 11, 2016: Moberg Pharma Announces Positive Phase II Data for BUPI
Jun 24, 2015: Moberg Pharma To Receive Eurostars Grant Of Eur 0.9 Million
Oct 28, 2014: First Patient Included in Phase ll Study of BUPI, a Novel Topical Formulation for Treatment of Oral Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Oral Mucositis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Oral Mucositis - Pipeline by Alivio Therapeutics Inc, H2 2020
Oral Mucositis - Pipeline by Allander Biotechnologies LLC, H2 2020
Oral Mucositis - Pipeline by BIOCND Inc, H2 2020
Oral Mucositis - Pipeline by Clevexel Pharma SAS, H2 2020
Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, H2 2020
Oral Mucositis - Pipeline by Humanetics Corp, H2 2020
Oral Mucositis - Pipeline by Lakewood-Amedex Inc, H2 2020
Oral Mucositis - Pipeline by Matrix Biomed Inc, H2 2020
Oral Mucositis - Pipeline by Moberg Pharma AB, H2 2020
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2020
Oral Mucositis - Dormant Projects, H2 2020
Oral Mucositis - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Oral Mucositis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Alivio Therapeutics Inc
• Allander Biotechnologies LLC
• BIOCND Inc
• Clevexel Pharma SAS
• GlycoMira Therapeutics Inc
• Humanetics Corp
• Lakewood-Amedex Inc
• Matrix Biomed Inc
• Moberg Pharma AB
• Spectrum Pharmaceuticals Inc